Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Endo Tools Therapeutics Secures EUR 2.5 Million in Second Round Funding

Published: Wednesday, September 11, 2013
Last Updated: Wednesday, September 11, 2013
Bookmark and Share
The investment provides Endo Tools Therapeutics with funding for clinical trials in obesity treatment, to take place in 2013 and 2014.

Endo Tools Therapeutics has announced the closure of a second round of funding worth EUR 2.5 million (USD 3.3 million) led by a private investor with an existing interest in medical devices.

Endo Tools Therapeutics, a spin-off from the Universite Libre in Brussels, Belgium, is developing Endomina™, an innovative device that adds degrees of freedom and a number of therapeutic channels to existing endoscopes.

Endomina provides gastroenterologists and surgeons with the capability to perform complex movements and use multiple instruments when operating.

It also gives them the freedom to perform manipulations which were previously possible only via laparoscopic access.

These devices offer new possibilities for advances in flexible endoscopy and for the treatment of serious conditions such as obesity, type II diabetes and tumors of the digestive system.

For the patient, the reduced requirement for anesthesia associated with Endomina means a shorter stay in hospital, even treatment as an outpatient, and improved comfort.

For hospitals and health systems, Endomina means a reduction in the overall cost of intervention. More than 200,000 procedures of this type are carried out each year in Europe, representing a market worth EUR 2 billion (USD 2.6 billion).

The first clinical trials, led by Professor Jacques Deviere at Erasme hospital in Brussels, Belgium, demonstrated that the operations were safe and workable.

They also helped Endo Tools Therapeutics to identify a number of ways to improve its products so that, for example, a stomach volume reduction can be carried out more quickly and easily, making the tools accessible to all operating gastroenterologists.

The funding will support the production of these new devices and the award of CE mark approval within the next few months. It will also enable the launch of a pan-European clinical study (in France, Germany, Belgium and Italy).

This is intended to demonstrate the efficacy and durability of complex sutures for suturing together the opposing walls of the stomach (using inverted sutures to join serosa to serosa/mucosa to mucosa) in the primary treatment of morbid obesity and in repeat bypass surgery.

The initial results of the pilot study of 10 to 15 patients are expected in the first quarter of 2014, to be followed in the third quarter by the results of the multi-center study of around 75 patients.

These studies will enable the launch of the health insurance reimbursement process in the major European countries.

In addition to this new funding, Endo Tools Therapeutics will also have access to its new partner's accumulated experience in medical devices.

Technological synergies have already been identified, particularly with regard to knowledge and access to advanced materials and manufacturing processes.

“For years, gastroenterologists have been limited to line-of-sight movements in their practice of endoscopy. Endomina offers them the option of working with both hands, performing complex procedures such as tying a suture knot inside the stomach, something which has not been possible up until now,” said Professor Jacques Deviere, director of the Department of Gastroenterology at Erasme hospital. “I think this is the first step towards real endoluminal surgery.”

“We are delighted with this new round of funding, which will help us to develop our Endomina technology, offering a solution that provides a true complement to current surgical techniques in the treatment of obesity, type II diabetes and cancers of the digestive system,” said Alexandre Chau, CEO of Endo Tools Therapeutics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ETT Completes First-in-Human Cases With its Endomina Triangulation Platform
Results confirm the safety and efficacy of the device and will lead to an extended clinical trial in 2013 at four key centers in Europe.
Friday, October 05, 2012
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!